Magnetic Resonance Imaging (MRI)-Guided Rectal Cancer Preservation Program
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MR-Guided Irradiation.
- Who it may be relevant to
- Registry conditions: Rectal Cancer. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
MRI-guided Rectal Cancer Preservation Program
Overview
The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of rectal preservation
Detailed description
HYPOTHESIS
The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a TNT Program renders improved TME-free rates due to the better visualization and online dose-adaptation of the Gross Tumor Volume (GTV).
Rationale In the radiation setting, MRI provides superior soft tissue contrast compared to standard onboard X-ray imaging improving inter- and intra- observer delineation variation. MRgRT offers the opportunity to adapt the plan at each fraction to the anatomical changes seen. This is especially important in rectal cancer where the rectum is subject to interfractional position changes, volume shrinkage and intrafractional shape and size variation due to the variability in rectal filling.
Primary Objectives
A. To achieve 3-year TME-free survival of 75% while keeping 3-year DFS rates of 75%.
B. To achieve a CTCAE v5 grade 2-3 proctitis of less than 10% and grade 2-3 rectal bleeding rate of \<2% at 2 years.
C. To achieve a Wexner Continence score of at least 90% over baseline at 2 years.
Secondary Objectives
A. Determination of blood and urine biomarkers of treatment response and toxicity .
B. Determination of radiomics biomarkers of treatment response and toxicity . C. Determination of rectal functionality with the Wexner Continence Score.
Interventions
- Radiation MR-Guided Irradiation
MR-Guided Irradiation
Primary outcome measures
- Total Mesorectal Excision (TME)-free survival [Time frame: 5-years]
Secondary outcome measures (2)
- Proctitis/Rectal Bleeding [Time frame: 5-years]
- Fecal Continence [Time frame: 5-years]
Eligibility criteria
Inclusion criteria
- Patients aged 18 or older with primary Stage II (T3-4, N0) or Stage III (any T, N1-2) biopsy-proven rectal cancer
- No prior radiation therapy to the target areas;
- ECOG 0-2 with medical status not contraindicating treatment with radical intent including TNT and TME (if required) and with basal laboratory values as follows:
- Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
- Platelets ≥ 50,000 cells/mm3.
- Hemoglobin ≥ 8.0 g/dl.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 4 x upper limit of normal.
- Total bilirubin < 2 x upper normal mg/dL.
- Alkaline phosphatase < 4 x upper limit of normal.
Exclusion criteria
- Patient unable to undergo an MRI examination
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07134296 · 2024.173